Abbvie ABBV
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Abbvie (ABBV) Business Model and Operations Summary
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Key Insights
Abbvie (ABBV) Core Market Data and Business Metrics
Latest Closing Price
$206.27Market Cap
$365.44 BillionPrice-Earnings Ratio
71.87Total Outstanding Shares
1.77 Billion SharesTotal Employees
50,000Dividend
$1.64 Per Share QuarterlyIPO Date
December 10, 2012SIC Description
Pharmaceutical PreparationsPrimary Exchange
New York Stock ExchangeHeadquarters
1 North Waukegan Road, North Chicago, IL, 60064
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $-6.03 Billion |
| Net Cash Flow From Financing Activities, Continuing | $-2.80 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-19.75 Billion |
| Net Cash Flow, Continuing | $-6.03 Billion |
| Net Cash Flow From Operating Activities | $16.51 Billion |
| Net Cash Flow From Investing Activities | $-19.75 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit, Deferred | $-2.07 Billion |
| Net Income/Loss Available To Common Stockholders, Basic | $5.09 Billion |
| Revenues | $55.53 Billion |
| Interest Expense, Operating | $2.67 Billion |
| Benefits Costs and Expenses | $35.25 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $9 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $5.09 Billion |
| Other Comprehensive Income/Loss | $-29 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $9 Million |
| Comprehensive Income/Loss | $5.10 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Assets | $23.34 Billion |
| Inventory | $4.45 Billion |
| Current Assets | $27.79 Billion |
| Equity | $6.07 Billion |
| Equity Attributable To Parent | $6.03 Billion |
| Liabilities And Equity | $143.42 Billion |
Historical Dividends
Current dividend: $1.64 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Feb 13, 2025 | May 15, 2025 | Apr 15, 2025 | $1.64 | Quarterly |
| Oct 30, 2024 | Feb 14, 2025 | Jan 15, 2025 | $1.64 | Quarterly |
| Sep 6, 2024 | Nov 15, 2024 | Oct 15, 2024 | $1.55 | Quarterly |
| Jun 20, 2024 | Aug 15, 2024 | Jul 15, 2024 | $1.55 | Quarterly |
| Feb 15, 2024 | May 15, 2024 | Apr 15, 2024 | $1.55 | Quarterly |
| Oct 27, 2023 | Feb 15, 2024 | Jan 16, 2024 | $1.55 | Quarterly |